The 5th Generation Tele-Robotic-Assisted Percutaneous Coronary Intervention: A First-in-Human Trial

Coronary Artery Disease Clinical Trial

Official title:

The 5th Generation Tele-Robotic-Assisted Percutaneous Coronary Intervention: A First-in-Human Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06213714
• Other study ID #: 5G Tele-Robotic-Assisted PCI
• Status: Not yet recruiting
• Phase: N/A
• Start date: February 2024
• Est. completion date: September 2024

Study information

• Verified date: January 2024
• Source: Yan'an Affiliated Hospital of Kunming Medical University
• Contact: Qiang Xue
• Phone: 13987199913
• Email: Xueqiang3513[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to examine the safety and effectiveness, from both clinical and technical perspectives, of utilizing the 5G-Robotic VRS100 system in percutaneous coronary intervention (PCI).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 12
• Est. completion date: September 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• General Inclusion Criteria:

1. Age =18 years.

2. Patients with coronary artery disease undergoing Percutaneous Coronary Intervention (PCI).

3. The subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.

• Angiographic Inclusion Criteria:

1. De-novo coronary artery disease.

2. Reference vessel diameter is 2.5-4.0mm by visual estimate.

3. Target lesion length is =30.0mm.

4. Target lesion is a single de-novo native coronary artery lesion. This lesion may consist of multiple lesions (with =10mm between diseased segments) and must be completely covered by a single stent with =5.0mm of normal segments on proximal and distal edges of the lesion.

5. Target lesion diameter showing stenosis =70% by visual estimate, or =50% with myocardial ischemia.

6. Target lesion angiography meets the calculation criteria of Rui-Xin AngioQFA, and AngioQFA is =0.8.

Exclusion Criteria:

• Patients meeting any of the following criteria will be excluded:

• General Exclusion Criteria:

1. Subjects with indications for urgent PCI surgery.

2. Evidence of an acute myocardial infarction within one week prior to the intended VRS100 procedure.

3. Subject has undergone PCI within 72 hours prior to the VRS100 procedure.

4. Subject has undergone PCI within 30 days prior to the VRS100 procedure and experienced a MACE or a serious adverse event (SAE).

5. Severe heart failure (NYHA IV & LVEF=35%).

6. Subject has suffered a stroke, or has an active peptic ulcer or upper gastrointestinal bleeding within 6 months prior to planned VRS100 procedure.

7. Subject has known hypersensitivity or contraindication to aspirin, heparin, ticagrelor, clopidogrel, bivalirudin, PTX(paclitaxel), stainless steel, etc.

8. Subject has acute or chronic kidney disease (serum creatinine level of >2.5 mg/dL or >221 umol/L) or need dialysis.

9. Pregnant or breastfeeding, or planning to be pregnant.

10. Repeated enrollment.

11. Any other factors that the researchers consider not suitable for inclusion or completion of this study.

• Angiographic Exclusion Criteria:

1. Any previous stent placement within 5.0 mm (proximal or distal) of the target lesion.

2. Target lesion requires planned treatment with directional coronary atherectomy (DCA), laser, rotational atherectomy or any device except for balloon dilatation prior to stent placement.

3. Cardiac allograft vasculopathy (CAV).

4. Target lesion/vessel has evidence of intraluminal thrombus.

5. Chronic total occlusion (CTO).

6. Target lesion located in a native vessel distal to an ostial, bifurcation or anastomosis.

7. Unprotected left main coronary artery disease defined as an obstruction greater than 50% diameter stenosis in the left main coronary artery.

8. Target lesion or vessel proximal to the target lesion has severe tortuosity or calcification.

9. Target lesion that cannot be fully covered by a single stent.

10. More than 2 lesions requires treatment in one vessel.

11. Subject requires treatment of more than one vessel.

Related Conditions & MeSH terms

• Arteriosclerosis
• Cardiovascular Diseases
• Coronary Artery Disease
• Coronary Disease
• Ischemia
• Myocardial Ischemia

Intervention

Device:
• 5G Tele-Robotic-Assisted PCI
The 5G Tele-Robotic-Assisted VRS100 system is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
Yan'an Affiliated Hospital of Kunming Medical University	Kunming Chenggong District People's Hospital, Shanghai Zhongshan Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical Success	Defined as angiographic success (residual stenosis after stenting of <30% with final TIMI [Thrombolysis In Myocardial Infarction] flow grade 3) without an in-hospital major adverse cardiovascular event (MACE) (cardiovascular death, MI, clinically driven target vessel revascularization).	48 hours or hospital discharge, whichever occurs first
Primary	Technical Success	Defined as the successful advancement and retraction of PCI devices using the VRS100 System and without conversion to manual operation.	1 day
Secondary	PCI Procedure Time	Defined as the time measured from the insertion of the guide catheter until the removal of the guide catheter.	During procedure
Secondary	Overall Procedure Time	Defined as the time measured from the insertion of the hemostasis sheath until the removal of the guide catheter.	During procedure
Secondary	Fluoroscopy and/or X-Ray Time	As recorded by an X-Ray System utilized during the procedure.	During procedure
Secondary	Patient Radiation Exposure - Cumulative Dose	Cumulative dose (mGy) as recored during the procedure.	During procedure
Secondary	Contrast Fluid Volume	The amount of contrast fluid used (mL) during the procedure.	During procedure